Document:

Exhibit 4.3

 

STATEMENT OF RESOLUTION ESTABLISHING SERIES
 OF
 FIXED RATE NON-VOTING PERPETUAL NON-CUMULATIVE PREFERRED STOCK, SERIES H
 OF
 MIDLAND STATES BANCORP, INC.

 

Pursuant to and in accordance with Section 6.10 of the Illinois Business Corporation Act of 1983, the undersigned corporation made the following statement:

 

ARTICLE 1

 

The name of the corporation is Midland States Bancorp, Inc. (the “Issuer”).

 

ARTICLE 2

 

That pursuant to the authority vested in the board of directors of the Issuer (the “Board of Directors”) in accordance with the provisions of the Articles of Incorporation of the Issuer (the “Articles”), the Board of Directors on January 25, 2017, adopted the following resolution creating a series of 2,636 shares of preferred stock designated as “Fixed Rate Non-Voting Perpetual Non-Cumulative Preferred Stock, Series H”:

 

RESOLVED, that pursuant to the authority vested in the Board of Directors in accordance with the provisions of the Articles, a series of preferred stock of the Issuer is hereby created, such series to be known as Fixed Rate Non-Voting Perpetual Non-Cumulative Preferred Stock, Series H, and that the designation and number of shares of such series, and the voting and other powers, preferences and relative, participating, optional or other rights of the shares of such series, and the qualifications, limitations and restrictions thereof are as follows:

 

Part 1. Designation and Number of Shares. There is hereby created out of the authorized and unissued shares of preferred stock of the Issuer a series of preferred stock designated as the “Fixed Rate Non-Voting Perpetual Non-Cumulative Preferred Stock, Series H” (the “Designated Preferred Stock”). The authorized number of shares of Designated Preferred Stock shall be 2,636.

 

Part 2. Standard Provisions. The Standard Provisions contained in Schedule A attached hereto are incorporated herein by reference in their entirety and shall be deemed to be a part of this Statement of Resolution Establishing Series to the same extent as if such provisions had been set forth in full herein.

 

Part. 3. Definitions. The following terms are used in this Statement of Resolution Establishing Series (including the Standard Provisions in Schedule A hereto) as defined below:

 

(a)                                 “Common Stock” means the common stock, par value $0.01 per share, of the Issuer.

 

(b)                                 “Dividend Payment Date” means March 31, June 30, September 30 and December 31 of each year, commencing on the first such date after the Original Issue Date.

 

(c)                                  “Junior Stock” means the Common Stock, and any other class or series of stock of the Issuer the terms of which expressly provide that it ranks junior to Designated Preferred Stock as to dividend rights and/or as to rights on liquidation, dissolution or winding up of the Issuer.

 

(d)                                 “Liquidation Amount” means $1,000 per share of Designated Preferred Stock.

 

(e)                                  “Original Issue Date” means the date on which shares of Designated Preferred Stock are first issued.

 

(f)                                   “Parity Stock” means any class or series of stock of the Issuer (other than Designated Preferred Stock) the terms of which do not expressly provide that such class or series will rank senior or junior to Designated Preferred Stock as to dividend rights and/or as to rights on liquidation, dissolution or

 

1

 

winding up of the Issuer (in each case without regard to whether dividends accrue cumulatively or non-cumulatively). Without limiting the foregoing, Parity Stock shall include the Issuer’s Fixed Rate Preferred Stock, Series G.

 

Part. 4. Certain Voting Matters. Holders of shares of Designated Preferred Stock will be entitled to one vote for each such share on any matter on which holders of Designated Preferred Stock are entitled to vote, including any action by written consent.

 

[Remainder of Page Intentionally Left Blank]

 

2

 

Schedule A

 

STANDARD PROVISIONS

 

Section 1. General Matters. Each share of Designated Preferred Stock shall be identical in all respects to every other share of Designated Preferred Stock. The Designated Preferred Stock shall be perpetual, subject to the provisions of Section 5 of these Standard Provisions that form a part of the Statement of Resolution Establishing Series. The Designated Preferred Stock shall rank equally with Parity Stock and shall rank senior to Junior Stock with respect to the payment of dividends and the distribution of assets in the event of any dissolution, liquidation or winding up of the Issuer.

 

Section 2. Standard Definitions. As used herein with respect to Designated Preferred Stock:

 

(a)                                 “Applicable Dividend Rate” means 12.500% per annum.

 

(b)                                 “Appropriate Federal Banking Agency” means the “appropriate Federal banking agency” with respect to the Issuer as defined in Section 3(q) of the Federal Deposit Insurance Act (12 U.S.C. Section 1813(q)), or any successor provision.

 

(c)                                  “Business Day” means any day except Saturday, Sunday and any day on which banking institutions in the State of Illinois generally are authorized or required by law or other governmental actions to close.

 

(d)                                 “Bylaws” means the bylaws of the Issuer, as they may be amended from time to time.

 

(e)                                  “Charter” means the Issuer’s certificate or articles of incorporation, articles of association, or similar organizational document.

 

(f)                                   “Dividend Period” means the period from and including any Dividend Payment Date to, but excluding, the next Dividend Payment Date.

 

(g)                                  “Dividend Record Date” has the meaning set forth in Section 3(b).

 

(h)                                 “Liquidation Preference” has the meaning set forth in Section 4(a).

 

(i)                                     “Preferred Director” has the meaning set forth in Section 7(b).

 

(I)                                   “Preferred Stock” means any and all series of preferred stock of the Issuer, including the Designated Preferred Stock.

 

(j)                                    “Standard Provisions” mean these Standard Provisions that form a part of the Statement of Resolution Establishing Series relating to the Designated Preferred Stock.

 

(k)                                 “Statement of Resolution Establishing Series” means the Statement of Resolution Establishing Series or comparable instrument relating to the Designated Preferred Stock, of which these Standard Provisions form a part, as it may be amended from time to time.

 

(l)                                     “Voting Parity Stock” means, with regard to any matter as to which the holders of Designated Preferred Stock are entitled to vote as specified in Sections 7(a) and 7(b) of these Standard Provisions that form a part of the Statement of Resolution Establishing Series, any and all series of Parity Stock upon which like voting rights have been conferred and are exercisable with respect to such matter.

 

Section 3. Dividends.

 

(a)                                 Rate. Holders of Designated Preferred Stock shall be entitled to receive, on each share of Designated Preferred Stock if, as and when declared by the Board of Directors or any duly authorized committee of

 

3

 

the Board of Directors, but only out of assets legally available therefor, non-cumulative cash dividends with respect to each Dividend Period, an amount equal to one-fourth (1/4) of the Applicable Dividend Rate on the Liquidation Amount per share of Designated Preferred Stock, and no more, payable in arrears on each Dividend Payment Date.

 

(b)                                 Dividend Payment Dates. In the event that any Dividend Payment Date would otherwise fall on a day that is not a Business Day, the dividend payment due on that date will be postponed to the next day that is a Business Day and no additional dividends will accrue as a result of that postponement. For the avoidance of doubt, “payable in arrears” means that, with respect to any particular Dividend Period, dividends begin accruing on the first day of such Dividend Period and are payable on the first day of the next Dividend Period.

 

Dividends that are payable on Designated Preferred Stock in respect of any Dividend Period shall be computed on the basis of a 360-day year consisting of twelve 30-day months. The amount of dividends payable on Designated Preferred Stock on any date prior to the end of a Dividend Period shall be computed on the basis of a 360-day year consisting of twelve 30-day months, and actual days elapsed over a 30-day month.

 

Dividends that are payable on Designated Preferred Stock on any Dividend Payment Date will be payable to holders of record of Designated Preferred Stock as they appear on the stock register of the Issuer on the applicable record date, which shall be the 15th calendar day immediately preceding such Dividend Payment Date or such other record date fixed by the Board of Directors or any duly authorized committee of the Board of Directors that is not more than 60 nor less than 10 days prior to such Dividend Payment Date (each, a “Dividend Record Date”). Any such day that is a Dividend Record Date shall be a Dividend Record Date whether or not such day is a Business Day.

 

Holders of Designated Preferred Stock shall not be entitled to any dividends, whether payable in cash, securities or other property, other than dividends (if any) declared and payable on Designated Preferred Stock as specified in this Section 3 (subject to the other provisions of the Statement of Resolution Establishing Series).

 

(c)                                  Non-Cumulative. Dividends on shares of Designated Preferred Stock shall be non-cumulative. If the Board of Directors or any duly authorized committee of the Board of Directors does not declare a dividend on the Designated Preferred Stock in respect of any Dividend Period, the holders of Designated Preferred Stock shall have no right to receive any dividend for such Dividend Period, and the Issuer shall have no obligation to pay a dividend for such Dividend Period, whether or not dividends are declared for any subsequent Dividend Period with respect to the Designated Preferred Stock.

 

(d)                                 Priority of Dividends.

 

(i)                                     Subject to Section 3(d)(ii) and any restrictions imposed by the Appropriate Federal Banking Agency or, if applicable, the Issuer’s state bank supervisor (as defined in Section 3(r) of the Federal Deposit Insurance Act (12 U.S.C. § 1813(q)), so long as any share of Designated Preferred Stock remains outstanding, the Issuer may declare and pay dividends on the Common Stock, any other shares of Junior Stock, or Parity Stock, in each case only if full dividends on all outstanding shares of Designated Preferred Stock for the most recently completed Dividend Period have been or are contemporaneously declared and paid.

 

(ii)                                  If a dividend is not declared and paid in full on the Designated Preferred Stock in respect of any Dividend Period, then from the last day of such Dividend Period until the last day of the third Dividend Period immediately following it, no dividend or distribution shall be declared or paid on the Common Stock or any other shares of Junior Stock (other than dividends payable solely in shares of Common Stock) or Parity Stock; provided, however, that in any such Dividend Period in which a dividend is declared and paid on the Designated Preferred Stock, dividends may be paid on Parity Stock to the extent necessary to avoid any material breach of a covenant by which the Issuer is bound.

 

(iii)                               Subject to the foregoing, and not otherwise, such dividends (payable in cash, securities or other property) as may be determined by the Board of Directors or any duly authorized committee of the Board of Directors may be declared and paid on any securities, including Common Stock and other Junior

 

4

 

Stock, from time to time out of any funds legally available for such payment, and holders of Designated Preferred Stock shall not be entitled to participate in any such dividends.

 

Section 4. Liquidation Rights,

 

(a)                                 Voluntary or Involuntary Liquidation. In the event of any liquidation, dissolution or winding up of the affairs of the Issuer, whether voluntary or involuntary, holders of Designated Preferred Stock shall be entitled to receive for each share of Designated Preferred Stock, out of the assets of the Issuer or proceeds thereof (whether capital or surplus) available for distribution to shareholders of the Issuer, subject to the rights of any creditors of the Issuer, before any distribution of such assets or proceeds is made to or set aside for the holders of Common Stock and any other stock of the Issuer ranking junior to Designated Preferred Stock as to such distribution, payment in full in an amount equal to the sum of (i) the Liquidation Amount per share and (ii) the amount of any declared and unpaid dividends for prior Dividend Periods on each such share (such amounts collectively, the “Liquidation Preference”).

 

(b)                                 Partial Payment. If in any distribution described in Section 4(a) above the assets of the Issuer or proceeds thereof are not sufficient to pay in full the amounts payable with respect to all outstanding shares of Designated Preferred Stock and the corresponding amounts payable with respect of any other stock of the Issuer ranking equally with Designated Preferred Stock as to such distribution, holders of Designated Preferred Stock and the holders of such other stock shall share ratably in any such distribution in proportion to the full respective distributions to which they are entitled.

 

(c)                                  Residual Distributions. If the Liquidation Preference has been paid in full to all holders of Designated Preferred Stock and the corresponding amounts payable with respect of any other stock of the Issuer ranking equally with Designated Preferred Stock as to such distribution has been paid in full, the holders of other stock of the Issuer shall be entitled to receive all remaining assets of the Issuer (or proceeds thereof) according to their respective rights and preferences.

 

(d)                                 Merger, Consolidation and Sale of Assets Not Liquidation. For purposes of this Section 4, the merger or consolidation of the Issuer with any other corporation or other entity, including a merger or consolidation in which the holders of Designated Preferred Stock receive cash, securities or other property for their shares, or the sale, lease or exchange (for cash, securities or other property) of all or substantially all of the assets of the Issuer, shall not constitute a liquidation, dissolution or winding up of the Issuer.

 

Section 5. Redemption

 

(a)                                 Optional Redemption. The Issuer, at its option, subject to the approval of the Appropriate Federal Banking Agency, if then required under applicable law, may redeem, in whole or in part, at any time and from time to time, on or after July 29, 2019, out of funds legally available therefor, the shares of Designated Preferred Stock at the time outstanding, upon notice given as provided in Section 5(c) below, at a redemption price equal to:

 

(i)                                     the Liquidation Amount per share;

 

(ii)                                  the per-share amount of any declared but unpaid dividends for prior Dividend Periods; and

 

(iii)                               the per-share amount of any accrued but unpaid dividends for the then current Dividend Period at the Applicable Dividend Rate to, but excluding, the date fixed for redemption.

 

The redemption price for any shares of Designated Preferred Stock shall be payable on the redemption date to the holder of such shares against surrender of the certificate(s) evidencing such shares to the Issuer or its agent. Any declared but unpaid dividends payable on a redemption date that occurs subsequent to the Dividend Record Date for a Dividend Period shall not be paid to the holder entitled to receive the redemption price on the redemption date, but rather shall be paid to the holder of record of the redeemed shares on such Dividend Record Date relating to the Dividend Payment Date as provided in Section 3 above.

 

5

 

(b)                                 No Sinking Fund. The Designated Preferred Stock will not be subject to any mandatory redemption, sinking fund or other similar provisions. Holders of Designated Preferred Stock will have no right to require redemption or repurchase of any shares of Designated Preferred Stock.

 

(c)                                  Notice of Redemption. Notice of every redemption of shares of Designated Preferred Stock shall be given by first class mail, postage prepaid, addressed to the holders of record of the shares to be redeemed at their respective last addresses appearing on the books of the Issuer. Such mailing shall be at least 30 days and not more than 60 days before the date fixed for redemption. Any notice mailed as provided in this Subsection shall be conclusively presumed to have been duly given, whether or not the holder receives such notice, but failure duly to give such notice by mail, or any defect in such notice or in the mailing thereof, to any holder of shares of Designated Preferred Stock designated for redemption shall not affect the validity of the proceedings for the redemption of any other shares of Designated Preferred Stock. Notwithstanding the foregoing, if shares of Designated Preferred Stock are issued in book-entry form through The Depository Trust Company or any other similar facility, notice of redemption may be given to the holders of Designated Preferred Stock at such time and in any manner permitted by such facility. Each notice of redemption given to a holder shall state: (i) the redemption date; (ii) the number of shares of Designated Preferred Stock to be redeemed and, if less than all the shares held by such holder are to be redeemed, the number of such shares to be redeemed from such holder; (iii) the redemption price; and (iv) the place or places where certificates for such shares are to be surrendered for payment of the redemption price.

 

(d)                                 Partial Redemption. In case of any redemption of part of the shares of Designated Preferred Stock at the time outstanding, the shares to be redeemed shall be selected either pro rata or in such other manner as the Board of Directors or a duly authorized committee thereof may determine to be fair and equitable. Subject to the provisions hereof, the Board of Directors or a duly authorized committee thereof shall have full power and authority to prescribe the terms and conditions upon which shares of Designated Preferred Stock shall be redeemed from time to time. If fewer than all the shares represented by any certificate are redeemed, a new certificate shall be issued representing the unredeemed shares without charge to the holder thereof.

 

(e)                                  Effectiveness of Redemption. If notice of redemption has been duly given and if on or before the redemption date specified in the notice all funds necessary for the redemption have been deposited by the Issuer, in trust for the pro rata benefit of the holders of the shares called for redemption, with a bank or trust company having a capital and surplus of at least $500 million and selected by the Board of Directors, so as to be and continue to be available solely therefor, then, notwithstanding that any certificate for any share so called for redemption has not been surrendered for cancellation, on and after the redemption date dividends shall cease to accrue on all shares so called for redemption, all shares so called for redemption shall no longer be deemed outstanding and all rights with respect to such shares shall forthwith on such redemption date cease and terminate, except only the right of the holders thereof to receive the amount payable on such redemption from such bank or trust company, without interest. Any funds unclaimed at the end of three years from the redemption date shall, to the extent permitted by law, be released to the Issuer, after which time the holders of the shares so called for redemption shall look only to the Issuer for payment of the redemption price of such shares.

 

(f)                                   Status of Redeemed Shares. Shares of Designated Preferred Stock that are redeemed, repurchased or otherwise acquired by the Issuer shall revert to authorized but unissued shares of Preferred Stock (provided that any such cancelled shares of Designated Preferred Stock may be reissued only as shares of any series of Preferred Stock other than Designated Preferred Stock).

 

Section 6. Conversion. Holders of Designated Preferred Stock shares shall have no right to exchange or convert such shares into any other securities.

 

Section 7. Voting Rights.

 

(a)                                 General. The holders of Designated Preferred Stock shall not have any voting rights except as set forth below or as otherwise from time to time required by law.

 

(b)                                 Preferred Stock Directors. Whenever, at any time or times, dividends payable on the shares of Designated Preferred Stock have not been declared and paid in full within 5 Business Days after each Dividend

 

6

 

Payment Date for an aggregate of eight quarterly Dividend Periods or more, whether or not consecutive, the authorized number of directors of the Issuer shall automatically be increased by two and the holders of the Designated Preferred Stock shall have the right, with holders of shares of any one or more other classes or series of Voting Parity Stock outstanding at the time, voting together as a class, to elect two directors (hereinafter the “Preferred Directors” and each a “Preferred Director”) to fill such newly created directorships at the Issuer’s next annual meeting of shareholders (or, if the next annual meeting is not yet scheduled or is scheduled to occur more than 30 days later, the President of the Issuer shall promptly call a special meeting for that purpose) and at each subsequent annual meeting of shareholders until full dividends have been paid on the Designated Preferred Stock for at least four consecutive Dividend Periods, at which time such right shall terminate with respect to the Designated Preferred Stock, except as herein or by law expressly provided, subject to revesting in the event of each and every subsequent default of the character above mentioned; provided that it shall be a qualification for election for any Preferred Director that the election of such Preferred Director shall not cause the Issuer to violate any corporate governance requirements of any securities exchange or other trading facility on which securities of the Issuer may then be listed or traded that listed or traded companies must have a majority of independent directors. Upon any termination of the right of the holders of shares of Designated Preferred Stock and Voting Parity Stock as a class to vote for directors as provided above, the Preferred Directors shall cease to be qualified as directors, the term of office of all Preferred Directors then in office shall terminate immediately and the authorized number of directors shall be reduced by the number of Preferred Directors elected pursuant hereto. Any Preferred Director may be removed at any time, with or without cause, and any vacancy created thereby may be filled, only by the affirmative vote of the holders of a majority of the shares of Designated Preferred Stock at the time outstanding voting separately as a class together with the holders of shares of Voting Parity Stock, to the extent the voting rights of such holders described above are then exercisable. If the office of any Preferred Director becomes vacant for any reason other than removal from office as aforesaid, the remaining Preferred Director may choose a successor who shall hold office for the unexpired term in respect of which such vacancy occurred.

 

(c)                                  Class Voting Rights as to Particular Matters. So long as any shares of Designated Preferred Stock are outstanding, in addition to any other vote or consent of shareholders required by law or by the Charter, the vote or consent of the holders of the majority of the outstanding shares of Designated Preferred Stock at the time outstanding, voting as a separate class, given in person or by proxy, either in writing without a meeting or by vote at any meeting called for the purpose, shall be necessary for effecting or validating:

 

(i)                                     Authorization of Senior Stock. Any amendment or alteration of the Statement of Resolution Establishing Series for the Designated Preferred Stock or the Charter to authorize or create or increase the authorized amount of, or any issuance of, any shares of, or any securities convertible into or exchangeable or exercisable for shares of, any class or series of capital stock of the Issuer ranking senior to Designated Preferred Stock with respect to either or both the payment of dividends and/or the distribution of assets on any liquidation, dissolution or winding up of the Issuer;

 

(ii)                                  Amendment of Designated Preferred Stock. Any amendment, alteration or repeal of any provision of the Statement of Resolution Establishing Series for the Designated Preferred Stock or the Charter (including, unless no vote on such merger or consolidation is required by Section 7(c)(iii) below, any amendment, alteration or repeal by means of a merger, consolidation or otherwise) so as to adversely affect the rights, preferences, privileges or voting powers of the Designated Preferred Stock; or

 

(iii)                               Share Exchanges, Reclassifications, Mergers and Consolidations. Any consummation of a binding share exchange or reclassification involving the Designated Preferred Stock, or of a merger or consolidation of the Issuer with another corporation or other entity, unless in each case (A) the shares of Designated Preferred Stock remain outstanding or, in the case of any such merger or consolidation with respect to which the Issuer is not the surviving or resulting entity, are converted into or exchanged for preference securities of the surviving or resulting entity or its ultimate parent, and (B) such shares remaining outstanding or such preference securities, as the case may be, have such rights, preferences, privileges and voting powers, and limitations and restrictions thereof, taken as a whole, as are not materially less favorable to the holders thereof than the rights, preferences, privileges and voting powers, and limitations and restrictions of Designated Preferred Stock immediately prior to such consummation, taken as a whole; provided, however, that for all purposes of this Section 7(c), any increase in the amount

 

7

 

of the authorized Preferred Stock, including any increase in the authorized amount of Designated Preferred Stock necessary to satisfy preemptive or similar rights granted by the Issuer to other persons prior to the Original Issue Date, or the creation and issuance, or an increase in the authorized or issued amount, whether pursuant to preemptive or similar rights or otherwise, of any other series of Preferred Stock, or any securities convertible into or exchangeable or exercisable for any other series of Preferred Stock, ranking equally with and/or junior to Designated Preferred Stock with respect to the payment of dividends (whether such dividends are cumulative or non-cumulative) and the distribution of assets upon liquidation, dissolution or winding up of the Issuer will not be deemed to adversely affect the rights, preferences, privileges or voting powers, and shall not require the affirmative vote or consent of, the holders of outstanding shares of the Designated Preferred Stock.

 

(d)                                 Changes after Provision for Redemption. No vote or consent of the holders of Designated Preferred Stock shall be required pursuant to Section 7(c) above if, at or prior to the time when any such vote or consent would otherwise be required pursuant to such Section, all outstanding shares of the Designated Preferred Stock shall have been redeemed, or shall have been called for redemption upon proper notice and sufficient funds shall have been deposited in trust for such redemption, in each case pursuant to Section 5 above.

 

(e)                                  Procedures for Voting and Consents. The rules and procedures for calling and conducting any meeting of the holders of Designated Preferred Stock (including, without limitation, the fixing of a record date in connection therewith), the solicitation and use of proxies at such a meeting, the obtaining of written consents and any other aspect or matter with regard to such a meeting or such consents shall be governed by any rules of the Board of Directors or any duly authorized committee of the Board of Directors, in its discretion, may adopt from time to time, which rules and procedures shall conform to the requirements of the Charter, the Bylaws, and applicable law and the rules of any national securities exchange or other trading facility on which Designated Preferred Stock is listed or traded at the time.

 

Section 8. Record Holders. To the fullest extent permitted by applicable law, the Issuer and the transfer agent for Designated Preferred Stock may deem and treat the record holder of any share of Designated Preferred Stock as the true and lawful owner thereof for all purposes, and neither the Issuer nor such transfer agent shall be affected by any notice to the contrary.

 

Section 9. Notices. All notices or communications in respect of Designated Preferred Stock shall be sufficiently given if given in writing and delivered in person or by first class mail, postage prepaid, or if given in such other manner as may be permitted in this Statement of Resolution Establishing Series, in the Charter or Bylaws or by applicable law. Notwithstanding the foregoing, if shares of Designated Preferred Stock are issued in book-entry form through The Depository Trust Company or any similar facility, such notices may be given to the holders of Designated Preferred Stock in any manner permitted by such facility.

 

Section 10. No Preemptive Rights. No share of Designated Preferred Stock shall have any rights of preemption whatsoever as to any securities of the Issuer, or any warrants, rights or options issued or granted with respect thereto, regardless of how such securities, or such warrants, rights or options, may be designated, issued or granted.

 

Section 11. Replacement Certificates. The Issuer shall replace any mutilated certificate at the holder’s expense upon surrender of that certificate to the Issuer. The Issuer shall replace certificates that become destroyed, stolen or lost at the holder’s expense upon delivery to the Issuer of reasonably satisfactory evidence that the certificate has been destroyed, stolen or lost, together with any indemnity that may be reasonably required by the Issuer.

 

Section 12. Other Rights. The shares of Designated Preferred Stock shall not have any rights, preferences, privileges or voting powers or relative, participating, optional or other special rights, or qualifications, limitations or restrictions thereof, other than as set forth herein or in the Charter or as provided by applicable law.

 

8

 

FURTHER RESOLVED, that the statements contained in the foregoing resolutions creating and designating the said issue of Fixed Rate Non-Voting Perpetual Non-Cumulative Preferred Stock, Series H and fixing the number, powers, preferences and relative, optional, participating, and other special rights and the qualifications, limitations, restrictions, and other distinguishing characteristics thereof shall, upon the effective date of said series, be deemed to be included in and be a part of the articles of incorporation, as amended, of Midland States Bancorp, Inc. pursuant to the provisions of the Illinois Business Corporation Act.

 

IN WITNESS WHEREOF, Midland States Bancorp, Inc. has caused this Statement of Resolution Establishing Series to be signed this [   ] day of [        ], 2017, by a duly authorized officer, who affirms, under penalties of perjury, that the facts stated herein are true.

 

	
MIDLAND STATES BANCORP, INC.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
Name:
    	
Douglas J. Tucker
    	
 
    
	
Title:
    	
Senior Vice President and Corporate Counsel
    	
 
    

 

9Exhibit 10.1

 

1010 Stony Hill Road, Suite 200

Yardley, PA 19067

Tel: 215.702.8550

 

March 13, 2017

 

Celgene Corporation

86 Morris Avenue

Summit, New Jersey 07901

Attention: Office of General Counsel

 

Re: Side Letter - Securities Purchase Agreement

 

Reference is made
to that certain Securities Purchase Agreement, dated as of February 27, 2017 (the “Purchase Agreement”),
by and between Alliqua BioMedical, Inc., a Delaware corporation (the “Company”), and Celgene Corporation,
a Delaware corporation (“Celgene”), pursuant to which the Company issued and sold to Celgene, and Celgene
purchased from the Company, 4,000,000 shares of common stock of the Company. Reference is further made to that certain warrant
issued by the Company to Celgene on November 18, 2013 (the “2013 Warrant”) and that certain warrant
issued by the Company to Celgene on April 14, 2014 (the “2014 Warrant” and together with the 2013 Warrant,
the “Warrants”). All capitalized terms in this letter (the “Letter Agreement”)
shall have the meanings assigned to them under the Purchase Agreement, unless otherwise defined herein.

 

By signature and countersignature
below, the Company and Celgene agree to the following:

 

		1)	Conditional Waiver of MFN.
                                         Effective as of February 27, 2017, the provisions of Section 4.15 of the Purchase Agreement
                                         are hereby waived to the extent that the MFN Adjustment would cause Celgene (together
                                         with its affiliates) to beneficially own (as determined in accordance with Section 13(d)
                                         of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
                                         thereunder) in excess of 19.9% of the number of shares of Common Stock outstanding immediately
                                         after giving effect to such MFN Adjustment (the “Maximum MFN Aggregate Ownership
                                         Amount”) or control in excess of 19.9% of the total voting power of the
                                         Company's securities outstanding immediately after giving effect to such MFN Adjustment
                                         that are entitled to vote on a matter being voted on by holders of the Common Stock (the
                                         “Maximum MFN Aggregate Voting Amount”) until the earlier of
                                         (i) the Company obtaining stockholder approval of resolutions approving the issuance
                                         of any securities to Celgene as a result of the MFN Adjustment in excess of the Maximum
                                         MFN Aggregate Ownership Amount or Maximum MFN Aggregate Voting Amount, as the case may
                                         be, pursuant to Nasdaq Listing Rule 5635(b) (the “MFN Stockholder Approval”)
                                         or (ii) or a Change of Control (as hereinafter defined). If as a result of any MFN Adjustment,
                                         the issuance of any Company securities to Celgene would exceed the Maximum MFN Warrant
                                         Aggregate Ownership Amount or the Maximum MFN Warrant Aggregate Voting Amount, and the
                                         Company shall not have previously obtained MFN Stockholder Approval, then the Company
                                         shall issue to Celgene such number of Company securities as may be issued below the Maximum
                                         MFN Aggregate Ownership Amount or Maximum MFN Aggregate Voting Amount, as the case may
                                         be, and, with respect to the remaining securities that would otherwise be issuable to
                                         Celgene as a result of the MFN Adjustment, such securities shall be held in abeyance
                                         until MFN Stockholder Approval has been obtained or the occurrence of a Change of Control.
                                         “Change of Control” means any consolidation or merger of the
                                         Company with or into any other corporation or other entity or person, or any other corporate
                                         reorganization in which the Company shall not be the continuing or surviving entity of
                                         such reorganization or any transaction or series of related transactions by the Company
                                         in which in excess of 50% of the Company’s voting power is transferred, or a sale
                                         of all or substantially all of the assets of the Company, other than any transaction
                                         or series of related transactions which is primarily for the purpose of financing the
                                         Company or a reincorporation of the Company.

 

     

     

    

 

		2)	Warrant Share Cap.

 

		a.	Notwithstanding anything in the Warrants
                                         to the contrary, the Company shall not issue to Celgene any shares of Common Stock issuable
                                         upon exercise of the Warrants (the “Warrant Shares”), to the
                                         extent such shares after giving effect to such issuance after exercise, Celgene (together
                                         with its affiliates) would (a) beneficially own (as determined in accordance with Section
                                         13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations
                                         promulgated thereunder) in excess of 19.9% of the number of shares of Common Stock outstanding
                                         immediately after giving effect to such issuance (the “Maximum Warrant Aggregate
                                         Ownership Amount”) or (b) control in excess of 19.9% of the total voting
                                         power of the Company's securities outstanding immediately after giving effect to such
                                         issuance that are entitled to vote on a matter being voted on by holders of the Common
                                         Stock (the “Maximum Warrant Aggregate Voting Amount”), unless
                                         and until the Company obtains stockholder approval permitting such issuances in accordance
                                         with Nasdaq Listing Rule 5635(b) (the “Warrant Stockholder Approval”).

 

		b.	If on any attempted exercise of any
                                         Warrant, the issuance of Warrant Shares would exceed the Maximum Warrant Aggregate Ownership
                                         Amount or the Maximum Warrant Aggregate Voting Amount, and the Company shall not have
                                         previously obtained Warrant Stockholder Approval at the time of exercise, then the Company
                                         shall issue to Celgene such number of Warrant Shares as may be issued below the Maximum
                                         Warrant Aggregate Ownership Amount or Maximum Warrant Aggregate Voting Amount, as the
                                         case may be, and, with respect to the remainder of the aggregate number of Warrant Shares,
                                         this Warrant shall not be convertible until and unless Warrant Stockholder Approval has
                                         been obtained or the occurrence of a Change of Control.

 

    2 

     

    

 

		3)	Shareholder Approval.

 

		a.	The Company shall provide each Company
                                         stockholder entitled to vote at an annual or special meeting of stockholders of the Company
                                         (the “Stockholder Meeting”), which meeting shall be promptly
                                         called and held no later than May 31, 2017 (the “Stockholder Meeting Deadline”),
                                         a proxy statement meeting the requirements of Section 14 of the Securities Exchange Act
                                         of 1934, as amended, and the related rules and regulations promulgated thereunder (the
                                         “Proxy Statement”) soliciting the MFN Stockholder Approval
                                         and Warrant Stockholder Approval in accordance with applicable law, the rules and regulations
                                         of the NASDAQ Stock Market, the Company's certificate of incorporation and bylaws and
                                         the General Corporation Law of the State of Delaware, and the Company shall use its reasonable
                                         best efforts to solicit the MFN Stockholder Approval and Warrant Stockholder Approval
                                         and to cause the board of directors of the Company to recommend to the Company stockholders
                                         that they approve the MFN Stockholder Approval and Warrant Stockholder Approval.

 

		b.	The Proxy Statement shall be in a
                                         form reasonably acceptable to Celgene and accordingly, the Company shall provide Celgene
                                         with reasonable opportunity to review and comment on the Proxy Statement. The Company
                                         shall keep Celgene apprised of the status of matters relating to the Proxy Statement
                                         and the Stockholder Meeting, including promptly furnishing Celgene with copies of notices
                                         or other communications related to the Proxy Statement, the Stockholder Meeting or the
                                         transactions contemplated hereby received by the Company from the Commission or the NASDAQ
                                         Stock Market. If either the MFN Stockholder Approval or Warrant Stockholder Approval
                                         is not obtained on or prior to the Stockholder Meeting Deadline, the Company shall cause
                                         an additional Stockholder Meeting to be held every three (3) months thereafter until
                                         such MFN Stockholder Approval and/or Warrant Stockholder Approval is obtained, as the
                                         case may be.

 

		4)	Integration. Except as otherwise
                                         modified pursuant to the paragraphs above, no other changes or modifications to the Purchase
                                         Agreement or the Warrants are intended or implied and in all other respects the Purchase
                                         Agreement and the Warrants are specifically deemed ratified, restated and confirmed by
                                         the parties hereto, effective as of the date hereof. To the extent that there exists
                                         any conflict between the terms of this Letter Agreement and the Purchase Agreement or
                                         the Warrants, the terms of this Letter Agreement shall control. This Letter Agreement
                                         together with the Purchase Agreement and the Warrants shall be read and construed as
                                         one agreement.

 

Please return an executed,
counter-signed copy of this Letter Agreement to the Company.

 

[Signature Page
Follows]

 

    3 

     

    

 

[Signature Page to Side Letter]

 

	 	Very truly yours,
	 	 
	 	Alliqua BioMedical, Inc.
	 	 	 
	 	By:	/s/ Brian
    M. Posner
	 	Name:  	Brian M. Posner
	 	Title: 	CFO

 

Acknowledged and Agreed:

Celgene Corporation

 

	By:	/s/
    Jonathan Biller 	 
	 	Name:	Jonathan Biller	 
	 	Title:	Senior VP, Tax & Treasury	 

 

    4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]